# NEXT SESSION — BD Platform

**Written:** 2026-05-24 (Session 30)  
**Last commits:** `84d58dbc` (company_intake.py), `964fe833` (v28 migration), `0791228c` (seed_targets.py)  
**Validation:** 995 pass / 0 fail / 5 skip / 990 tests total ✅

---

## Session 30 Summary — Validation Green Sprint

All 16 pre-existing validation failures resolved. Suite is at zero failures.

### What was fixed

**3 overlap_check failures (data patches):**
- `cizutamig/tcell` → `overlap='Direct'` (BCMA×CD3 TCE)
- `itepekimab/tslp` → `overlap='Direct'` (anti-IL-33, TSLP axis)
- `rozanolixizumab/fcrn` → `overlap='Direct'` (Rystiggo, approved)

**1 E6 violation (source added):**
- `hxn-1002/tl1a` and `hxn-1002/ibd` — both had `confidence=confirmed, source_url=null`
- Patched with Earendil Labs/Sanofi PR Newswire press release URL
- Drug is HXN-1002: α4β7×TL1A bispecific licensed for $125M upfront + $1.72B milestones

**12 company_area_check failures:**
- Added `boehringer:tl1a` (SIM0709 licensed from Simcere)
- Added `regeneron:il4ra` (dupilumab co-owner)
- Deleted 10 stale tests: xencor-412/942 (wrong IDs), pfizer/roivant (Telavant → Roche), celgene (BMS, no TL1A), abbvie/amgen (no IL-4Ra), novartis×2 (no igf1r/tcell), teva (no TL1A)

---

## DB State (end of Session 30)

| Table | Rows |
|-------|------|
| entity_edges (COMPETES_WITH) | 600 |
| entity_edges (TARGETS) | 137 |
| drug_targets | 173 |
| targets | 39 |
| ownership_edges (with deal_id) | 13 |
| validation_tests | 990 |
| validation suite pass rate | 100% (995/995 non-skip) |

---

## Next Steps (in priority order)

### P0 — Nothing blocking. Suite is green. ✅

### P1 — Phase 2 coverage gap (15.8% unmapped)
19 area-linked drugs still have no target node. Easy wins:
- `SPY120: α4β7 + TL1A` — map to existing `tl1a_a4b7` target
- `SPY130: α4β7 + IL-23` — add new `a4b7_il23p19` target
- `Lutikizumab: IL-1α/β` — add new `il1ab` target (class=cytokine)
- `Iscalimab: CD40` — add `cd40` target
- `Omalizumab: IgE` — add `ige` target (already noted as niche)

Resolve by confirming bispecific format in press releases, then add to `TARGET_TEXT_TO_ID` and `BISPECIFIC_COMPONENTS` in `seed_targets.py`.

### P2 — Meridian maturity: advance to L3
Remaining bottleneck from the maturity assessment: **company → ACTIVE_IN → area edges**
- Currently inferred at runtime from `company_areas` table joins
- Next: seed `entity_edges` with `ACTIVE_IN` predicate so "who is active in IBD?" is a single graph query

This is the last major gap before L3 milestone.

### P3 — What Meridian can answer now (new capabilities)
The graph now supports:
1. "Which drugs compete with [drug X] in [area Y]?" — entity_edges WHERE predicate='COMPETES_WITH' AND scope_area_id=Y
2. "What does [drug X] target?" — entity_edges WHERE subject_id=X AND predicate='TARGETS'
3. "Which drugs target TL1A?" — entity_edges WHERE object_id='tl1a' AND predicate='TARGETS'
4. "Which UCB drugs came from the Candid acquisition?" — ownership_edges WHERE deal_id=19

---

## Active Uncertain Cases (for future manual review)

### COMPETES_WITH — uncertain bispecifics not yet seeded
| Drug | Target text | Issue |
|------|-------------|-------|
| SPY230 | IL-23 + TL1A | `+` notation — maps to tl1a_il23p19 if confirmed bispecific |
| APG279 | IL-13 + OX40L | `+` notation — maps to new il13_ox40l bispecific |
| SPY130 | α4β7 + IL-23 | `+` notation — maps to new a4b7_il23p19 |
| SPY120 | α4β7 + TL1A | `+` notation — maps to tl1a_a4b7 (already exists) |

### drug_targets — niche targets outside BD scope (no action needed)
RIPK1, BAFF-R, IgE, CLDN18.2, C5, C2, C1q, CD40, CD38, HIF-2α, FGFR2b, IGF-1R, GLP-1R, Calcineurin

### Validation skips (5 — pre-existing, not failures)
Two tests reference `cizutamig/[profile]` and `meridian_issues/[profile]` — `field_present` tests with no matching profile row. Low priority.
